Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential.

Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, Qiao H, Reddy R, Leeper D, Chance B, Glickson JD.

Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6608-13. doi: 10.1073/pnas.0901807106. Epub 2009 Apr 6.

2.

Predicting melanoma metastatic potential by optical and magnetic resonance imaging.

Li LZ, Zhou R, Zhong T, Moon L, Kim EJ, Qiao H, Pickup S, Hendrix MJ, Leeper D, Chance B, Glickson JD.

Adv Exp Med Biol. 2007;599:67-78.

PMID:
17727249
3.

³¹P-MRS studies of melanoma xenografts with different metastatic potential.

Li LZ, Zhou R, Leeper DB, Glickson JD.

Adv Exp Med Biol. 2011;701:69-73. doi: 10.1007/978-1-4419-7756-4_10.

PMID:
21445771
4.

Characterizing breast cancer mouse xenografts with T₁ρ -MRI: a preliminary study.

Li LZ, Xu HN, Reddy R.

Adv Exp Med Biol. 2011;701:137-42. doi: 10.1007/978-1-4419-7756-4_19.

PMID:
21445780
5.

Quantitative mitochondrial redox imaging of breast cancer metastatic potential.

Xu HN, Nioka S, Glickson JD, Chance B, Li LZ.

J Biomed Opt. 2010 May-Jun;15(3):036010. doi: 10.1117/1.3431714.

6.

Histological basis of MR/optical imaging of human melanoma mouse xenografts spanning a range of metastatic potentials.

Xu HN, Zhou R, Nioka S, Chance B, Glickson JD, Li LZ.

Adv Exp Med Biol. 2009;645:247-53. doi: 10.1007/978-0-387-85998-9_37.

PMID:
19227478
7.

Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line.

Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ.

Int J Cancer. 1991 Jan 21;47(2):227-37.

PMID:
1671030
8.

Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential.

Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL Jr, et al.

J Natl Cancer Inst. 1992 Feb 5;84(3):165-74.

PMID:
1371813
9.

Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.

Øvrebø KM, Ellingsen C, Hompland T, Rofstad EK.

Acta Oncol. 2013 Apr;52(3):604-11. doi: 10.3109/0284186X.2012.689851. Epub 2012 Jun 7.

PMID:
22671573
10.

Distinct regulation of pHin and [Ca2+]in in human melanoma cells with different metastatic potential.

Martínez-Zaguilán R, Martinez GM, Gomez A, Hendrix MJ, Gillies RJ.

J Cell Physiol. 1998 Jul;176(1):196-205.

PMID:
9618159
11.

Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.

Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e121-7. doi: 10.1016/j.ijrobp.2011.12.019. Epub 2012 Feb 28.

PMID:
22381901
12.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential.

Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV.

J Comput Assist Tomogr. 2017 Sep/Oct;41(5):823-827. doi: 10.1097/RCT.0000000000000598.

PMID:
28448404
13.

Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.

Øvrebø KM, Gulliksrud K, Mathiesen B, Rofstad EK.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):255-61. doi: 10.1016/j.ijrobp.2011.04.008.

PMID:
21816291
14.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

NMR Biomed. 2005 Aug;18(5):308-21.

PMID:
15918178
15.

Characterizing prostate tumor mouse xenografts with CEST and MT-MRI and redox scanning.

Cai K, Xu HN, Singh A, Haris M, Reddy R, Li LZ.

Adv Exp Med Biol. 2013;765:39-45. doi: 10.1007/978-1-4614-4989-8_6.

16.

Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.

Egeland TA, Simonsen TG, Gaustad JV, Gulliksrud K, Ellingsen C, Rofstad EK.

Radiat Res. 2009 Sep;172(3):339-47. doi: 10.1667/RR1787.1.

PMID:
19708783
17.

In vivo metabolic evaluation of breast tumor mouse xenografts for predicting aggressiveness using the hyperpolarized (13)C-NMR technique.

Xu HN, Kadlececk S, Pullinger B, Profka H, Cai K, Hariharan H, Rizi R, Li LZ.

Adv Exp Med Biol. 2013;789:237-42. doi: 10.1007/978-1-4614-7411-1_32.

18.

The metastasis suppressor KISS1 lacks antimetastatic activity in the C8161.9 xenograft model of melanoma.

Navenot JM, Evans B, Oishi S, Setsuda S, Fujii N, Peiper SC.

Melanoma Res. 2012 Apr;22(2):140-50. doi: 10.1097/CMR.0b013e328350fa07.

PMID:
22395416
19.

Heterogeneity of mitochondrial redox state in premalignant pancreas in a PTEN null transgenic mouse model.

Xu HN, Nioka S, Chance B, Li LZ.

Adv Exp Med Biol. 2011;701:207-13. doi: 10.1007/978-1-4419-7756-4_28.

20.

Integrin expression in human melanoma cells with differing invasive and metastatic properties.

Gehlsen KR, Davis GE, Sriramarao P.

Clin Exp Metastasis. 1992 Mar;10(2):111-20.

PMID:
1311225

Supplemental Content

Support Center